General Information of Drug (ID: DML7YPS)

Drug Name
Duroquinone Drug Info
Synonyms
Duroquinone; 527-17-3; Tetramethyl-1,4-benzoquinone; Tetramethyl-p-benzoquinone; Tetramethylquinone; 2,3,5,6-Tetramethyl-1,4-benzoquinone; 2,3,5,6-tetramethylcyclohexa-2,5-diene-1,4-dione; Tetramethyl-p-quinone; 2,3,5,6-Tetramethylbenzoquinone; p-Benzoquinone, tetramethyl-; p-Benzoquinone, 2,3,5,6-tetramethyl-; 2,3,5,6-Tetramethyl-p-benzoquinone; 2,5-Cyclohexadiene-1,4-dione, 2,3,5,6-tetramethyl-; NSC 2068; CCRIS 2989; p-Benzoquinone, tetramethyl-, semiquinone; UNII-X0Q8791R69; EINECS 208-409-8
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
68238
ChEBI ID
CHEBI:42023
CAS Number
CAS 527-17-3
TTD Drug ID
DML7YPS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug(s) Targeting Quinone reductase 1 (NQO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARQ 761 DMH5CAL Pancreatic cancer 2C10 Phase 2 [3]
Coenzyme Q10 analog DMO0VGH Huntington disease 8A01.10 Phase 2 [4]
BioE-743 DM7PT8R Leigh syndrome 5C53.24 Phase 2 [5]
Flavin-Adenine Dinucleotide DM5S4GK Discovery agent N.A. Investigative [1]
NSC-645808 DMMBAR3 Discovery agent N.A. Investigative [6]
NSC-106080 DMR6P9S Discovery agent N.A. Investigative [7]
NSC-99528 DMXZAIG Discovery agent N.A. Investigative [7]
NSC-354279 DMVL51I Discovery agent N.A. Investigative [6]
Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate DMJQTIK Discovery agent N.A. Investigative [8]
3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one DMA5EHC Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Heme oxygenase 1 (HMOX1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [9]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [10]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [11]
Verapamil DMA7PEW Angina pectoris BA40 Approved [12]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [13]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [14]
Selenium DM25CGV N. A. N. A. Approved [15]
TECFIDERA DM2OVDT Multiple sclerosis 8A40 Approved [16]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [17]
Methotrexate DM2TEOL Anterior urethra cancer Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By NAD(P)H dehydrogenase 1 (NQO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [19]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [20]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [21]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [22]
TECFIDERA DM2OVDT Multiple sclerosis 8A40 Approved [23]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [24]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [25]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [26]
Quercetin DM3NC4M Obesity 5B81 Approved [27]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [28]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Quinone reductase 1 (NQO1) TT8XK6L NQO1_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Gene/Protein Processing [2]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Gene/Protein Processing [2]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Formation of Redox-Active Duroquinone from Vaping of Vitamin E Acetate Contributes to Oxidative Lung Injury. Chem Res Toxicol. 2022 Feb 21;35(2):254-264. doi: 10.1021/acs.chemrestox.1c00309. Epub 2022 Jan 25.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
7 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
8 Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
9 Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
10 Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
11 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
12 Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis. 2010;28(6):792-8. doi: 10.1159/000324287. Epub 2011 Apr 27.
13 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
14 Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
15 High selenium status in individuals exposed to arsenic through coal-burning in Shaanxi (PR of China) modulates antioxidant enzymes, heme oxygenase-1 and DNA damage. Clin Chim Acta. 2010 Sep 6;411(17-18):1312-8.
16 Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
17 Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep. 2008 Aug;20(2):379-84.
18 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
19 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
20 Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
21 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
22 Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
23 Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs. 2005 Feb;16(2):167-74.
24 Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
25 Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
26 P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
27 Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol Lett. 2001 Feb 3;119(1):49-57.
28 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.